Vaxcyte Stock Operating Margin
| PCVX Stock | USD 88.39 2.43 2.83% |
Vaxcyte fundamentals help investors to digest information that contributes to Vaxcyte's financial success or failures. It also enables traders to predict the movement of Vaxcyte Stock. The fundamental analysis module provides a way to measure Vaxcyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaxcyte stock.
| Last Reported | Projected for Next Year |
Vaxcyte | Operating Margin |
Vaxcyte Company Operating Margin Analysis
Vaxcyte's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Vaxcyte Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Vaxcyte is extremely important. It helps to project a fair market value of Vaxcyte Stock properly, considering its historical fundamentals such as Operating Margin. Since Vaxcyte's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vaxcyte's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vaxcyte's interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Based on the recorded statements, Vaxcyte has an Operating Margin of 0.0%. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The operating margin for all United States stocks is 100.0% lower than that of the firm.
Vaxcyte Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaxcyte's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaxcyte could also be used in its relative valuation, which is a method of valuing Vaxcyte by comparing valuation metrics of similar companies.Vaxcyte is currently under evaluation in operating margin category among its peers.
Vaxcyte ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vaxcyte's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vaxcyte's managers, analysts, and investors.Environmental | Governance | Social |
Vaxcyte Fundamentals
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | 8.86 B | ||||
| Shares Outstanding | 124.64 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 99.50 % | ||||
| Number Of Shares Shorted | 8.93 M | ||||
| Price To Book | 3.22 X | ||||
| Gross Profit | (23 M) | ||||
| EBITDA | (464.88 M) | ||||
| Net Income | (402.27 M) | ||||
| Cash And Equivalents | 354.5 M | ||||
| Cash Per Share | 5.98 X | ||||
| Total Debt | 29.22 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 11.94 X | ||||
| Book Value Per Share | 27.47 X | ||||
| Cash Flow From Operations | (296.79 M) | ||||
| Short Ratio | 12.89 X | ||||
| Earnings Per Share | (4.60) X | ||||
| Price To Earnings To Growth | (11.32) X | ||||
| Target Price | 151.75 | ||||
| Number Of Employees | 254 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 11.02 B | ||||
| Total Asset | 1.41 B | ||||
| Retained Earnings | (924.39 M) | ||||
| Working Capital | 950.62 M | ||||
| Net Asset | 1.41 B |
About Vaxcyte Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vaxcyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.